Kyverna Therapeutics, Inc.
KYTX
$9.40
$0.040.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.76% | 12.58% | 5.72% | -19.06% | -8.69% |
| Total Depreciation and Amortization | -11.33% | -19.42% | 2.79% | -11.01% | 0.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.23% | 36.98% | -0.93% | 930.18% | -114.18% |
| Change in Net Operating Assets | 119.59% | -207.61% | 476.69% | -6,523.53% | -99.35% |
| Cash from Operations | 22.61% | -35.59% | 28.87% | -21.19% | -34.82% |
| Capital Expenditure | 150.00% | 50.00% | -- | -- | -421.57% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -176.87% | -22.91% | 422.97% | -81.25% | 3,724.42% |
| Cash from Investing | -176.64% | -22.66% | 422.89% | -80.91% | 4,222.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 29.17% | 54.20% | 23.17% | -38.06% | -2.07% |
| Issuance of Common Stock | 6,940.64% | -- | -100.00% | -90.63% | -64.44% |
| Repurchase of Common Stock | -16.28% | 15.69% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -342.11% | -- | -- |
| Cash from Financing | 9,358.53% | 329.28% | -56.76% | -92.56% | -41.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 566.53% | -461.82% | 91.37% | -393.56% | 70.13% |